- Market Realist•11 minutes ago
Spinraza, Biogen’s (BIIB) SMA (spinal muscular atrophy) therapy, was approved by the FDA (U.S. Food and Drug Administration) on December 23, 2016.
- Motley Fool•1 hour ago
If President Trump cracks down on drug price inflation, these pharma and biotech offenders could be in big trouble.
- Market Realist•2 hours ago
In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||275.10 x 100|
|Ask||278.73 x 100|
|Day's Range||275.60 - 281.22|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.34|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|